Literature DB >> 20663292

Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease.

David J Bonda1, Maneesh Mailankot, Jeremy G Stone, Matthew R Garrett, Magdalena Staniszewska, Rudy J Castellani, Sandra L Siedlak, Xiongwei Zhu, Hyoung-gon Lee, George Perry, Ram H Nagaraj, Mark A Smith.   

Abstract

Tryptophan metabolism, through the kynurenine pathway, produces neurotoxic intermediates that are implicated in the pathogenesis of Alzheimer's disease. In particular, oxidative stress via 3-hydroxykynurenine (3-HK) and its cleaved product 3-hydroxyanthranilic acid (3-HAA) significantly damages neuronal tissue and may potentially contribute to a cycle of neurodegeneration through consequent amyloid-beta accumulation, glial activation, and up-regulation of the kynurenine pathway. To determine the role of the kynurenine pathway in eliciting and continuing oxidative stress within Alzheimer's diseased brains, we used immunocytochemical methods to show elevated levels of 3-HK modifications and the upstream, rate-limiting enzyme indoleamine 2,3-dioxygenase (IDO-1) in Alzheimer's diseased brains when compared to controls. Importantly, the association of IDO-1 with senile plaques was confirmed and, for the first time, IDO-1 was shown to be specifically localized in conjunction with neurofibrillary tangles. As senile plaques and neurofibrillary tangles are the pathological hallmarks of Alzheimer's disease, our study provides further evidence that the kynurenine pathway is involved with the destructive neurodegenerative pathway of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663292      PMCID: PMC2956440          DOI: 10.1179/174329210X12650506623645

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  54 in total

1.  Kynurenine pathway metabolism in human astrocytes.

Authors:  G J Guillemin; S J Kerr; G A Smythe; P J Armati; B J Brew
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

2.  Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior.

Authors:  Michelle C Potter; Greg I Elmer; Richard Bergeron; Edson X Albuquerque; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

3.  Physiological regulation of tau phosphorylation during hibernation.

Authors:  Bo Su; Xinglong Wang; Kelly L Drew; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

4.  Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

Authors:  C S Atwood; R D Moir; X Huang; R C Scarpa; N M Bacarra; D M Romano; M A Hartshorn; R E Tanzi; A I Bush
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

Review 5.  Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.

Authors:  T W Stone
Journal:  Prog Neurobiol       Date:  2001-06       Impact factor: 11.685

6.  The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway.

Authors:  H Wolf
Journal:  Scand J Clin Lab Invest Suppl       Date:  1974

7.  Effects of oxygen on 3-hydroxyanthranilate oxidase of the kynurenine pathway.

Authors:  Y Dang; C Xia; O R Brown
Journal:  Free Radic Biol Med       Date:  1998-12       Impact factor: 7.376

8.  Understanding the roles of the kynurenine pathway in multiple sclerosis progression.

Authors:  Chai K Lim; Bruce J Brew; Gayathri Sundaram; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2010-08-25

9.  Effects of Kynurenine Pathway Metabolites on Intracellular NAD Synthesis and Cell Death in Human Primary Astrocytes and Neurons.

Authors:  Nady Braidy; Ross Grant; Bruce J Brew; Seray Adams; Tharusha Jayasena; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-04-03

10.  The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.

Authors:  Abdur Rahman; Kaka Ting; Karen M Cullen; Nady Braidy; Bruce J Brew; Gilles J Guillemin
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

View more
  41 in total

Review 1.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

2.  Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

Authors:  Tao Ma; Yiran Chen; Valerie Vingtdeux; Haitian Zhao; Benoit Viollet; Philippe Marambaud; Eric Klann
Journal:  J Neurosci       Date:  2014-09-03       Impact factor: 6.167

3.  Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.

Authors:  Xiao-Dan Wang; Francesca M Notarangelo; Ji-Zuo Wang; Robert Schwarcz
Journal:  Brain Res       Date:  2012-03-17       Impact factor: 3.252

Review 4.  Kynurenines in the mammalian brain: when physiology meets pathology.

Authors:  Robert Schwarcz; John P Bruno; Paul J Muchowski; Hui-Qiu Wu
Journal:  Nat Rev Neurosci       Date:  2012-07       Impact factor: 34.870

5.  Searching for an endogenous anti-Alzheimer molecule: identifying small molecules in the brain that slow Alzheimer disease progression by inhibition of ß-amyloid aggregation.

Authors:  Autumn R Meek; Gordon A Simms; Donald F Weaver
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

Review 6.  Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass.

Authors:  David J Bonda; Xinglong Wang; Hyoung-Gon Lee; Mark A Smith; George Perry; Xiongwei Zhu
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

Review 7.  The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.

Authors:  Marta Amaral; Tiago F Outeiro; Nigel S Scrutton; Flaviano Giorgini
Journal:  J Mol Med (Berl)       Date:  2013-05-01       Impact factor: 4.599

Review 8.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

Review 9.  TDO as a therapeutic target in brain diseases.

Authors:  Cheng-Peng Yu; Ze-Zheng Pan; Da-Ya Luo
Journal:  Metab Brain Dis       Date:  2016-04-13       Impact factor: 3.584

10.  Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.

Authors:  Markus J Schwarz; Gilles J Guillemin; Stefan J Teipel; Katharina Buerger; Harald Hampel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-11-29       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.